+

PE20081303A1 - Composicion farmaceutica que comprende un inhibidor de desacetilasa de histona y un antimetabolito - Google Patents

Composicion farmaceutica que comprende un inhibidor de desacetilasa de histona y un antimetabolito

Info

Publication number
PE20081303A1
PE20081303A1 PE2007001696A PE2007001696A PE20081303A1 PE 20081303 A1 PE20081303 A1 PE 20081303A1 PE 2007001696 A PE2007001696 A PE 2007001696A PE 2007001696 A PE2007001696 A PE 2007001696A PE 20081303 A1 PE20081303 A1 PE 20081303A1
Authority
PE
Peru
Prior art keywords
alkyl
desacetilase
histone
pharmaceutical composition
composition including
Prior art date
Application number
PE2007001696A
Other languages
English (en)
Inventor
Peter Wisdom Atadja
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39272127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081303(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20081303A1 publication Critical patent/PE20081303A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: (a) UNA HDAC (INHIBIDORES DE DESACETILASA DE HISTONA) DE FORMULA (I) DONDE R1 ES H, HALOGENO, ALQUILO C1-C6, ENTRE OTROS; R2 ES H, ALQUILO C1-C10, CICLOALQUILO C4-C9, ENTRE OTROS; R3 Y R4 SON CADA UNO H, ALQUILO C1-C6, ACILO, ACIL AMINO, ENTRE OTROS; R5 ES H, ALQUILO C1-C6, CICLOALQUILO C4-C9, ENTRE OTROS; n1, n2 Y n3 SON 0-6; X E Y SON CADA UNO H, HALOGENO, ALQUILO C1-C4, ENTRE OTROS; (b) UN ANTI-METABOLITO TAL COMO 5-AZACITIDINA. UN HDAC ES N-HIDROXI-3-[4-[[[2-(2-METIL-1H-INDOL-3-IL)-ETIL]-AMINO]-METIL]-FENIL]-2E-2-PROPENAMIDA. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS
PE2007001696A 2006-12-04 2007-11-30 Composicion farmaceutica que comprende un inhibidor de desacetilasa de histona y un antimetabolito PE20081303A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86838806P 2006-12-04 2006-12-04

Publications (1)

Publication Number Publication Date
PE20081303A1 true PE20081303A1 (es) 2008-10-28

Family

ID=39272127

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001696A PE20081303A1 (es) 2006-12-04 2007-11-30 Composicion farmaceutica que comprende un inhibidor de desacetilasa de histona y un antimetabolito

Country Status (26)

Country Link
US (1) US8093220B2 (es)
EP (1) EP2099451B1 (es)
JP (3) JP5784274B2 (es)
KR (1) KR101475538B1 (es)
CN (1) CN101553223A (es)
AR (1) AR064072A1 (es)
AU (1) AU2007328281B2 (es)
BR (1) BRPI0719746A2 (es)
CA (1) CA2670741C (es)
CL (1) CL2007003467A1 (es)
EC (1) ECSP099483A (es)
ES (1) ES2569477T3 (es)
GT (1) GT200900148A (es)
HK (1) HK1132462A1 (es)
IL (1) IL198638A (es)
MA (1) MA30982B1 (es)
MX (1) MX2009005946A (es)
MY (1) MY148893A (es)
NO (1) NO20092473L (es)
PE (1) PE20081303A1 (es)
PL (1) PL2099451T3 (es)
RU (1) RU2469717C2 (es)
TN (1) TN2009000213A1 (es)
TW (1) TW200831075A (es)
WO (1) WO2008070011A2 (es)
ZA (1) ZA200903041B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2260020T3 (pl) * 2008-03-26 2015-01-30 Novartis Ag Hydroksamianowe inhibitory deacetylaz B
WO2010009285A1 (en) * 2008-07-18 2010-01-21 Novartis Ag Use of hdac inhibitors for the treatment of acute myeloid leukemia and/or myelodysplastic syndrome
US20110118309A1 (en) * 2008-07-18 2011-05-19 Peter Wisdom Atadja Use of hdac inhibitors for the treatment of hodgkin's disease
US20110053925A1 (en) * 2009-08-28 2011-03-03 Novartis Ag Hydroxamate-Based Inhibitors of Deacetylases
JP6031437B2 (ja) * 2010-06-07 2016-11-24 アブラクシス バイオサイエンス, エルエルシー 増殖性疾患を処置するための組み合わせ療法
RU2013114246A (ru) * 2010-09-01 2014-10-20 Новартис Аг Комбинация hdac ингибиторов с лекарственными средствами против тромбоцитопении
CA2903473A1 (en) 2013-03-12 2014-10-09 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
US9757385B2 (en) 2013-11-27 2017-09-12 Merck Sharp & Dohme Corp. Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds
WO2016044138A1 (en) 2014-09-17 2016-03-24 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
SG11201707418WA (en) 2015-03-13 2017-10-30 Forma Therapeutics Inc Alpha-cinnamide compounds and compositions as hdac8 inhibitors
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
JP2006528952A (ja) * 2003-05-21 2006-12-28 ノバルティス アクチエンゲゼルシャフト ヒストンデアセチラーゼ阻害剤と化学療法剤の組み合わせ

Also Published As

Publication number Publication date
TW200831075A (en) 2008-08-01
JP2016006070A (ja) 2016-01-14
AU2007328281B2 (en) 2011-03-31
NO20092473L (no) 2009-09-01
TN2009000213A1 (en) 2010-10-18
HK1132462A1 (zh) 2010-02-26
ECSP099483A (es) 2009-08-28
AU2007328281A1 (en) 2008-06-12
MY148893A (en) 2013-06-14
JP2010511702A (ja) 2010-04-15
EP2099451A2 (en) 2009-09-16
JP5784274B2 (ja) 2015-09-24
CA2670741A1 (en) 2008-06-12
WO2008070011A2 (en) 2008-06-12
ZA200903041B (en) 2010-03-31
US8093220B2 (en) 2012-01-10
CL2007003467A1 (es) 2008-07-11
MA30982B1 (fr) 2009-12-01
MX2009005946A (es) 2009-06-17
AR064072A1 (es) 2009-03-11
KR101475538B1 (ko) 2014-12-22
GT200900148A (es) 2011-08-02
RU2009125439A (ru) 2011-01-20
US20100069318A1 (en) 2010-03-18
RU2469717C2 (ru) 2012-12-20
IL198638A (en) 2015-06-30
KR20090087115A (ko) 2009-08-14
BRPI0719746A2 (pt) 2013-12-10
CA2670741C (en) 2016-04-12
EP2099451B1 (en) 2016-02-10
IL198638A0 (en) 2010-02-17
WO2008070011A3 (en) 2008-07-24
CN101553223A (zh) 2009-10-07
PL2099451T3 (pl) 2016-07-29
JP2014097992A (ja) 2014-05-29
ES2569477T3 (es) 2016-05-11

Similar Documents

Publication Publication Date Title
PE20081303A1 (es) Composicion farmaceutica que comprende un inhibidor de desacetilasa de histona y un antimetabolito
ECSP099576A (es) Combinación de lbh589 con otros agentes terapeuticos para
PE20090641A1 (es) Amidas heterociclicas
MX2010005298A (es) Compuestos de carboxamida, sulfonamida y amina para trastornos metabolicos.
CO6541569A2 (es) Inhibidores de n1-pirazoloespirocetona acetil-coa carboxilasa
ECSP11010770A (es) Compuesto heterocíclico y su uso
ATE455110T1 (de) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
SV2009002865A (es) Uso de oxazolidinonas para el tratamiento y profilaxis de microangiopatias
PE20080061A1 (es) Compuestos derivados de amida como inhibidores de los canales de potasio task-1 y task-3
BR112013030939A2 (pt) derivado de indazol e pirrolopiridina e uso farmacêutico do mesmo
PE20120561A1 (es) Compuestos que modulan selectivamente el receptor cb2
EA201270590A1 (ru) Ингибиторы акт
EA201170351A1 (ru) Способы лечения невропатической боли
EA201300436A8 (ru) Совместные кристаллы и соли ингибиторов ccr3
EA200802382A1 (ru) Соли n-гидрокси-3-[4-[[[2-(2-метил-1н-индол-3-ил)этил]амино]метил]фенил]-2е-2-пропенамида
PE20081383A1 (es) Inhibidores benzoimidazolicos de trpv1
MX2011007639A (es) Compuestos de carboxamida y metodos para usar los mismos.
GT200800280A (es) Polimorfo de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida
EA201101621A1 (ru) Производные бензоксазолона в качестве ингибиторов альдостеронсинтазы
CL2011001026A1 (es) Uso de pimobedan para preparar un medicamento util en el tratamiento de cardiomiopatia hipertrofica en un gato.
NI201000051A (es) Benzotiazoles como moduladores del receptor de grelina.
DOP2009000139A (es) Antagonistas nitroderivados del receptor de angiotensina ii
PE20091847A1 (es) Derivados de piridil-ptolinamida como antagonistas de receptores nk1
JO3192B1 (ar) مركب بنزوثيازولون
CR20110082A (es) Nuevos inhibidores de la proteina tirosina quinasa y receptores vegf-2 y uso farmacéutico de los mismos

Legal Events

Date Code Title Description
FC Refusal
点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载